B. Braun IV Saline Recall: Records Patients Should Preserve

On August 28, 2026, the U.S. Food and Drug Administration published B. Braun Medical Inc.'s voluntary nationwide recall of three lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB container. FDA's summary lists August 27 as the company announcement date, while the announcement body is datelined August 19. The recall reaches the hospital, healthcare-facility, and user level.

B. Braun identified the particulate matter as iron oxide. FDA states that, on August 28, the recalling firm updated the recall reason to correctly identify iron oxide rather than zinc oxide.

The FDA-hosted notice describes potentially life-threatening consequences if affected product is administered intravenously. When FDA published the notice on August 28, it stated that, "to date," there had been no reports of serious injury, death, or other adverse events associated with the issue.

Medical safety: If you think you received this product and have a medical concern, contact the treating physician or healthcare provider. Call 911 for an emergency. Do not stop, start, disconnect, or change IV treatment based on a recall article.

Important: This article provides general information, not legal or medical advice. Nationwide distribution does not prove that a California facility received or used a recalled lot. A recall, treatment record, symptom, or lot match does not automatically prove exposure, defect, negligence, causation, damages, or legal responsibility.

The Recall Covers Three Lots, Not All IV Saline

The recalled product can be identified by several fields that should be kept together:

• Product: B. Braun 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB container
• Catalog number: S8004-5264
• NDC: 0264-1800-32
• Lot numbers: J6B435, J6B444, and J6B457
• Expiration date: 30APR2027
• Distribution period: February 27 through August 3, 2026
• Distribution scope: hospitals and healthcare facilities nationwide

The notice does not recall every B. Braun sodium chloride product, every saline bag, or every IV fluid. A facility name, treatment date, or general reference to “saline” is not enough by itself to establish a match. The February 27–August 3 dates are distribution dates, not a patient-treatment-date cutoff.

What FDA's Risk Statement Says, and What It Does Not Say

The FDA-hosted company notice says administration of the affected product has a reasonable probability of causing life-threatening adverse consequences. It identifies possible pulmonary emboli, blockage of other blood vessels, phlebitis, systemic immune activation, organ dysfunction, and hemolysis.

Those are described risks. They are not a report that those outcomes occurred in an identified patient, and they are not a diagnosis for someone who received an IV.

Do not compare symptoms to a list and decide that a recalled lot caused them. A clinician must evaluate the person's history, treatment, timing, symptoms, tests, and other possible explanations. The recall notice itself says consumers who experienced problems that may relate to the product should contact their physician or healthcare provider.

A Patient May Never Have Seen the Saline Bag

This product was distributed through hospitals and healthcare facilities. It may have been used for hydration or as a diluent and delivery system for a compatible medication. The patient may remember the medication, procedure, emergency visit, infusion, or surgery without knowing which saline product was used.

That means the useful evidence may be spread across several systems:

• the patient's electronic health record;
• medication administration and nursing records;
• pharmacy dispensing or preparation records;
• barcode and automated-cabinet transactions;
• purchasing, receiving, and inventory records;
• distributor shipment records;
• facility recall, quarantine, return, and replacement records; and
• communications among the facility, pharmacy, distributor, and manufacturer.

Not every system will preserve the same identifier. A medical chart may show that saline was administered but omit the lot. A pharmacy or inventory record may show the lot but require a separate link to the patient's encounter. The task is to determine whether reliable records can connect the product and lot to the patient's encounter. A preservation request may identify relevant records, but it does not itself create access rights or stop routine retention or destruction.

Start With an Exact Treatment Timeline

Write down what you know without guessing:

• facility and address;
• treatment date and approximate time;
• emergency department, clinic, infusion center, surgery center, hospital unit, or other location;
• physician, nurse, infusion provider, pharmacy, or department names that appear in the records;
• procedure, medication, hydration, or treatment described to you;
• admission, discharge, transfer, and follow-up dates;
• portal messages, after-visit summaries, wristbands, labels, receipts, and bills.

Keep the original files and envelopes. Do not edit screenshots or combine several records into one image without also preserving the originals.

Ask the Facility a Narrow Product-Identification Question

A clear inquiry is more useful than accusing a facility of using contaminated saline.

Ask the facility to determine whether the encounter involved:

• B. Braun 0.9% Sodium Chloride Injection USP;
• 100 mL in a 150 mL PAB container;
• catalog number S8004-5264;
• NDC 0264-1800-32; or
• lot J6B435, J6B444, or J6B457.

Also ask where product identity would be recorded if it is not in the ordinary chart. The answer may involve a pharmacy, materials-management department, infusion service, outside contractor, distributor, or other custodian.

Record the date, method, recipient, and response for each inquiry. Do not trespass, enter medication storage, demand a used bag, remove facility property, or confront clinical staff. The facility must keep patient care and product control safe.

Our quick guide for checking recalled IV-saline records gives a short first-step checklist.

Request Medical and Billing Records, but Know Their Limits

The U.S. Department of Health and Human Services says the HIPAA Privacy Rule generally gives a person, with limited exceptions, the right to inspect, review, and receive copies of medical and billing records held by covered providers and health plans.

A focused request may include:

• orders and medication administration records;
• nursing and infusion flowsheets;
• procedure or anesthesia records;
• pharmacy records kept in the patient's designated record set;
• laboratory, imaging, discharge, and follow-up records;
• itemized billing and coding records; and
• portal messages and patient notifications.

That right does not mean every pharmacy inventory, purchasing, internal quality, peer-review, or risk-management record must appear in the patient's chart or be produced through an ordinary HIPAA request. Those records may be maintained separately and may be subject to different access, privacy, retention, or privilege rules.

A missing lot number in the chart does not prove that no lot-tracing record exists. It also does not prove that the recalled product was used.

Preserve Facility Recall and Lot-Tracing Records

If a specific encounter may have involved the recalled product, potentially relevant facility records may include:

• recall notices and the date each department received them;
• affected-product and affected-location lists;
• purchasing and distributor records;
• receiving, transfer, and stocking records;
• pharmacy cabinet, barcode, batch, or preparation logs;
• quarantine, return, destruction, and replacement records;
• lot-reconciliation or patient-tracing work;
• patient and clinician notifications; and
• communications with B. Braun, FDA, distributors, or regulators.

Do not assume every item exists or is available to the patient on request. A preservation request can identify records that may matter, but it does not automatically create access rights, override privacy or privilege, or stop every ordinary process.

Medical Records and Recall Records Must Be Compared Carefully

Even a reliable lot match answers only one part of the investigation. Other questions remain:

• Was the product administered directly or used as a diluent?
• How much was used and when?
• What medication or treatment accompanied it?
• What symptoms or findings were documented before and after administration?
• What did treating clinicians conclude?
• What alternative causes were evaluated?
• When did the facility, distributor, and manufacturer receive relevant information?
• What product remained available for inspection or testing?

A recall may be important evidence, but it is not a substitute for medical causation analysis. Similarly, a facility's use of a recalled lot does not by itself establish that the facility acted wrongfully. Manufacturer, distributor, pharmacy, facility, clinician, and contractor roles must be investigated separately.

MedWatch Is a Reporting Path, Not a Liability Decision

FDA's MedWatch program accepts reports from health professionals, patients, and consumers about suspected adverse events and product-quality problems involving human medical products, including medicines administered in hospitals and outpatient infusion centers.

Before reporting, save the information used in the submission, including the product identifiers, treatment date, facility, clinician records, symptoms, diagnoses, and other relevant products. Mark unknown fields as unknown rather than filling them with assumptions.

A MedWatch report does not replace medical care. It also does not determine whether the recalled product was used, caused an injury, was legally defective, or made any person or business responsible. It is separate from a facility report, manufacturer communication, insurance claim, regulatory investigation, or lawsuit.

Official Sources

• FDA: B. Braun 0.9% Sodium Chloride Injection recall
• FDA: MedWatch safety information and adverse-event reporting
• DailyMed: B. Braun sodium chloride injection label and NDC listing
• HHS: Your rights to medical and billing records

Review the current FDA recall page before acting. Recall instructions and status can change.

Bottom Line

If you think recalled B. Braun IV saline may have been used during your care, do not change treatment based on an article. Contact the treating provider about medical concerns. Preserve the treatment timeline, medical and billing records, product identifiers, pharmacy and facility lot-tracing records, recall communications, and any accurate clinical follow-up.

Law Office of Arta Wildeboer handles personal-injury matters for people and families in Downey, Southeast Los Angeles, the Gateway Cities, Los Angeles County, and Southern California. Learn about the firm's California personal-injury services, use the quick record-check guide, or request a free consultation about the specific facts.

Call (562) 608-8887. Arta speaks English, Spanish, and Farsi. Tagalog and Korean assistance are available through the office.

Past results do not promise any outcome. Contacting the firm does not create an attorney-client relationship unless a written agreement is signed.